PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsCommentWhy rare disease research isn't just about rare diseases

BioNews

Why rare disease research isn't just about rare diseases

Published 18 November 2013 posted in Comment and appears in BioNews 731

Author

Oliver Timmis

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

The idea of a rare disease informing wider knowledge about fundamentals of biology is now well established. We have shown it in alkaptonuria research, as alkaptonuria (which affects around 80 people in the UK) is an extreme form of osteoarthritis (which affects more than eight million)...

Alkaptonuria (AKU) is the focus of the AKU Society. It's a debilitating
disease, causing bones to turn black and brittle, leading to early joint
degeneration. Many patients are left disabled and in considerable pain.
However, for Sir Archibald Garrod and William Bateson, AKU helped them to
understand genetics.

Sir Archibald Garrod was a
true pioneer, relying on simple observations to understand fundamental aspects
of human biology. He was an Edwardian
doctor who specialised in metabolic
medicine before it was called that.

After treating several
patients with AKU, and looking at their family histories, he realised the
disease followed patterns. It was quite common for brothers and sisters of
patients to also have AKU; for grandparents to be as affected as their
grandchildren; and for it to be more common in the children of a consanguineous
marriage. He came to realise that AKU was somehow inheritable, centred around
an 'inborn error of metabolism'.

While investigating the mysteries of AKU, Sir Garrod became friends with
William Bateson, a Cambridge scientist with an interest in the work of Gregor
Mendel, the monk famous for early experiments into the genetics of garden peas.
Bateson realised that AKU and its inborn error was actually a Mendelian
recessive character; a compound that was inheritable along a predictable
pattern and which caused disease.

For the early 20th Century, this was groundbreaking. Ideas of inheritance and genetics were only
just being formed and there was little understanding of how diseases could
follow family lines. The work from Garrod and Bateson showed that a disease
could be inherited as determined by a biochemical compound. This helped develop
the idea of a genetic condition, and gave AKU its claim to fame as the world's
first genetic disease to be recognised as such.

Garrod went on to present AKU, along with three other inheritable diseases
(albinism, cystinuria and pentosuria) at a 1908 lecture. It was here that his
term, 'an inborn error of metabolism', became known and this eventually led to the creation of a medical society: the Society for the Study of Inborn Errors of Metabolism in 1963.

Bateson, meanwhile, took the AKU example and founded modern genetics. He
is even credited with naming the word 'genetics', along with the well-known terms
'heterozygote', 'homozygote' and 'allele'. In 1910, he founded a journal to
help explain this new phenomenon of science, called the Journal of Genetics.

Sir Garrod summed
up the importance of his research with rare diseases as: 'The study of nature's experiments is of special value; and many
lessons which rare maladies can teach could hardly be learned in other ways'.

William Bateson
used the more concise 'treasure your exceptions!'

This
idea of a rare disease informing wider knowledge about fundamentals of biology
is now well established. We have shown it in AKU research, as AKU (which affects around
80 people in the UK) is an extreme form of osteoarthritis (which affects more
than eight million).

Our
partners at the University of Liverpool compare bone samples from AKU patients
with osteoarthritis patients. They discovered 'trabecular excrescences' in AKU
bone — microscopic lumps created when the bone reacts to the disease. The
research team also found these excrescences in osteoarthritic bone; a discovery
about a disease affecting millions and that would not have been made without
AKU research.

There
are plenty more examples of the benefits of researching rare and extreme form
of diseases. I'll give just three examples: work on familial hypercholesterolemia led to the
development of statins to treat high cholesterol; congenital lipodystrophy,
which causes an inability to store fat correctly, led to a better understanding
of insulin resistance and diabetes; and a group of rare diseases called neuroacanthocytosis, marked by progressive muscle weakness and degeneration of
the brain, are now being studied to understand more about how the brain
deteriorates in common diseases such as Alzheimer's and Parkinson's.

That is why we founded a new charity, called Findacure: The Fundamental
Diseases Partnership. 'Fundamental diseases' is applied here to extreme and
rare genetic disorders, which offer a unique opportunity to better understand
other diseases, including many common conditions. We believe that by studying
fundamental diseases, we can understand the processes behind common diseases
and learn new methods for their treatment.

To find out more about fundamental diseases and
the role they play in understanding and treating other diseases, please see the
Findacure website
.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
15 May 2017 • 2 minutes read

Most people harbour at least one lethal mutation

by Chris Baldacci

Geneticists have estimated that each of us carries an average of one or two lethal, but recessive, genes in our DNA...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Reviews
24 February 2014 • 4 minutes read

Radio Review: Health Check - Would You Want to Find Out About an Inherited Genetic Condition?

by Simon Hazelwood-Smith

Genetic diagnosis of inherited diseases is now routine in the UK, with upwards of 600 different conditions tested for in NHS labs. As genetic sequencing and analysis methods become ever more effective, this figure should grow rapidly over the coming years...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
22 November 2013 • 1 minute read

First UK-wide rare disease strategy launched

by Dr Lucy Freem

A strategy to improve diagnosis, research, and treatment of rare diseases has been launched by the UK Government...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
25 October 2013 • 1 minute read

Rare Disease Genomes Project to sequence 10,000 whole genomes

by Dr Lucy Freem

A three-year joint project to sequence the genomes of 10,000 rare disease patients has been announced by the University of Cambridge, Genomics England and Illumina...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
4 October 2013 • 2 minutes read

Trial for rare 'black bone disease' wins funding

by Dr Shanya Sivakumaran

The Alkaptonuria Society, a UK charity and patient organisation for the rare disease of the same name, has won a £5million grant from the European Commission to help finance clinical trials of a treatment for the condition...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 September 2013 • 2 minutes read

Rare disease treatments risk being 'entirely out of patients' reach', says MPs report

by James Brooks

A parliamentary report has recommended a ring-fenced fund to ensure access to 'low volume, high cost' treatments for rare diseases...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
7 June 2013 • 3 minutes read

Global alliance to boost data-sharing in genetic research

by Dr Shanya Sivakumaran

Leading international healthcare, research, funding, and technology organisations will work together in a non-profit alliance to enable large-scale sharing of genetic data...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Screening dilemmas: disability, disease or something in-between?

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

FILM: 200 Years of Mendel – From Peas to Personalised Medicine

1 August 2022 • 4 minutes read

Women's Health Strategy plans reflect rising needs of same-sex female couples

25 July 2022 • 4 minutes read

Was the Women's Health Strategy worth the wait?

25 July 2022 • 4 minutes read

Why the UK should extend the 14-day rule to 28 days

25 July 2022 • 5 minutes read

200 Years of Mendel: From Peas to Personalised Medicine

15 August 2022 • 5 minutes read

Same-sex parent should not have been forced to adopt child

15 August 2022 • 2 minutes read

FILM: Editing the Human Genome – Where Are We Now? What Happens Next?

8 August 2022 • 4 minutes read

Citizenship and same-sex parents – about time, Sweden!

8 August 2022 • 2 minutes read

FILM: 200 Years of Mendel – From Peas to Personalised Medicine

1 August 2022 • 4 minutes read

Women's Health Strategy plans reflect rising needs of same-sex female couples

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856